Literature DB >> 20480795

Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance?

Megan A Kinney1, Brad A Yentzer, Alan B Fleischer, Steven R Feldman.   

Abstract

BACKGROUND: Acne vulgaris has been treated with long-term courses of antibiotics since the 1960s. Antibiotic-resistance of Propionibacterium acnes (P. acnes) was first documented in the late 1970s, and, over 20 years later, the problem of antibiotic resistance still exists.
PURPOSE: The aim of this study was to assess trends in prescribing antibiotics for acne from 1997-2006.
METHODS: The authors examined the National Ambulatory Medical Care Survey (NAMCS) database and recorded medications at all visits to the physician in which acne vulgaris (ICD-9-CM code 706.1) was the only diagnosis from 1997-2006.
RESULTS: Declines in the use of erythromycin and isotretinoin (both P < 0.001) for acne were noted for all physicians. Tetracyclines saw significant increases in use by both dermatologists and non-dermatologists (P < 0.01 and P = 0.05, respectively). Prescribing of benzoyl peroxide monotherapy was unchanged for non-dermatologists (P = 0.22) and is on the decline for dermatologists (P < 0.001). The use of BPO + clindamycin combination topical treatments rose sharply for all physicians (P < 0.001), resulting in greater use of both total BPO and total clindamycin for acne over time (P < 0.001). Topical retinoid use increased among dermatologists (P < 0.05) but appeared to be on the decline among non-dermatologists (P = 0.067).
CONCLUSION: The development of antibiotic resistance is of concern. Greater awareness of retinoid use for maintenance therapy, using topical benzoyl peroxide to prevent resistance, and limiting use of oral antibiotics to as short a time period as possible are measures to contribute to better eco-responsible acne treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480795

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  7 in total

1.  Synergy and its clinical reievance in topical acne therapy.

Authors:  Leon H Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2011-11

2.  Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model.

Authors:  Stephen C Davis; Andrew Harding; Joel Gil; Fernando Parajon; Jose Valdes; Michael Solis; Alex Higa
Journal:  Int Wound J       Date:  2017-03-07       Impact factor: 3.315

3.  Retinoid plus antimicrobial combination treatments for acne.

Authors:  Ashley N Feneran; William S Kaufman; Tushar S Dabade; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-07-01

4.  Development and Sequential Analysis of a New Multi-Agent, Anti-Acne Formulation Based on Plant-Derived Antimicrobial and Anti-Inflammatory Compounds.

Authors:  Crina Saviuc; Bianca Ciubucă; Gabriela Dincă; Coralia Bleotu; Veronica Drumea; Mariana-Carmen Chifiriuc; Marcela Popa; Gratiela Gradisteanu Pircalabioru; Luminita Marutescu; Veronica Lazăr
Journal:  Int J Mol Sci       Date:  2017-01-17       Impact factor: 5.923

5.  Origanum vulgare L. Essential Oil as a Potential Anti-Acne Topical Nanoemulsion-In Vitro and In Vivo Study.

Authors:  Mohammed H Taleb; Nourtan F Abdeltawab; Rehab N Shamma; Sherein S Abdelgayed; Sarah S Mohamed; Mohamed A Farag; Mohammed A Ramadan
Journal:  Molecules       Date:  2018-08-28       Impact factor: 4.411

6.  Evaluation of Therapeutic Effect and Prognosis of Danzhi Xiaoyao Powder Combined with Photodynamic Therapy in the Treatment of Rose Acne.

Authors:  Xinjian Yu; Ni Zhang; Jing Jin; Xuwen Yin; Jing Luo
Journal:  Comput Math Methods Med       Date:  2022-03-11       Impact factor: 2.238

7.  Antimicrobial and anti-inflammatory activity of chitosan-alginate nanoparticles: a targeted therapy for cutaneous pathogens.

Authors:  Adam J Friedman; Jenny Phan; David O Schairer; Jackson Champer; Min Qin; Aslan Pirouz; Karin Blecher-Paz; Ami Oren; Phil T Liu; Robert L Modlin; Jenny Kim
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.